Nanotechnology Characterization Laboratory (NCL)
The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics
Laboratory Overview
The NCL, as part of its Assay Cascade, performs physicochemical characterization, as well as in vitro and in vivo biocompatibility testing of nanoparticles intended as cancer therapies or diagnostics. Nanomaterials are accepted into the NCL via an application process and all characterization is performed at no charge to the submitting investigator.
 |
The NCL’s primary focus is on the translational development of nanotechnology-derived drugs and devices to promote their advancement into clinical trials. NCL resources and activities are prioritized to influence, inform, and accelerate the research and pre-clinical test phases for these materials. In addition, the novelty of the NCL set-up (access to a variety of sponsor-provided nanomaterial types) allows the NCL a unique opportunity for discovering nanoparticle trends, evaluating new mechanisms, and improving and defining methods for nanoparticle characterization. |
Additional information is available on the Nanotechnology Characterization Laboratory (NCL) website, the NCL Staff Directory or on the Application Process page.
